ADMA Biologics, Inc. (ADMA)

USD 17.7

(-4.99%)

Market Cap (In USD)

4.18 Billion

Revenue (In USD)

258.21 Million

Net Income (In USD)

-28.23 Million

Avg. Volume

4.86 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.07-23.64
PE
-
EPS
-
Beta Value
0.645
ISIN
US0008991046
CUSIP
000899104
CIK
1368514
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Adam S. Grossman
Employee Count
-
Website
https://www.admabiologics.com
Ipo Date
2013-10-17
Details
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

More Stocks